Across
- 5. Percutaneous Coronary Intervention versus Coronary-Artery Bypass Grafting for Severe Coronary Artery Disease
- 8. SGLT2 reduce the risk of hospitalization for heart failure and cardiovascular death among patients with HF mildly reduced EF
- 9. Reversed the paradigm rate first to rhythm first, early rhythm control reduces CV outcomes vs rate control alone
- 13. Eplerenone, as compared with placebo, reduced both the risk of death and the risk of hospitalization among patients with systolic heart failure and mild symptoms
- 14. Established Rate Control as first step in AF
- 15. First time combo of low dose NOACs + Antiplatelet reduces cardiovascular events in stable CAD
Down
- 1. First trial showed that inflammation reduction improves CV outcomes
- 2. Introduced ARNI IN HF
- 3. No mortality benefit with early invasive strategy vs optimal medical therapy in stable CAD
- 4. Shifted SGLT2i from Diabetes to Heart Failure
- 6. TAVI versus Surgical Aortic-Valve Replacement
- 7. Reperfusion involving the transfer of patients to an invasive-treatment center for primary angioplasty is superior to on-site fibrinolysis, provided that the transfer takes two hours or less
- 10. Patients receiving empagliflozine had a lower risk of CV death or hospitalization for heart failure than those in the placebo group, regardless of the presence or absence of diabetes
- 11. PCSK9i into Lipid Guidelines
- 12. MRA benefit in HFpEF